Tegumentary leishmaniasis is a concerning issue faced by public health systems in tropical and subtropical countries worldwide. While autochthonous cases of tegumentary leishmaniasis have been documented in all Brazilian states, the prevalence of tegumentary leishmaniasis is higher in the north and northeastern regions, which account for more than 70% of the cases in Brazil. In Brazil, Leishmania from different species can cause disease, but Leishmania (Viannia) braziliensis is the main causal agent of tegumentary leishmaniasis. Leishmania (V.) braziliensis can also cause different clinical forms of the disease such as cutaneous, mucosal, and disseminated leishmaniasis. Advances in the epidemiology, taxonomy, pathogenesis, immunology, and diagnosis of tegumentary leishmaniasis have been achieved in the last 20 years. However, additional studies are still needed in order to adapt these advances to clinical medicine to ameliorate the suffering of leishmaniasis patients. Moreover, very little is known about the development or identification of new drugs for leishmaniasis therapy. In the beginning of the last century, antimony was used to treat leishmaniasis and has been the therapy of choice for tegumentary leishmaniasis in Brazil ever since.
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In their review, Brito et al. emphasize the diversity among Leishmania species, which are a large number of phlebotomine species with the ability to transmit leishmania, and reservoir hosts of the parasites 2 . Among the biological sciences, the greatest advances related to leishmaniasis in recent years have been in the field of immunology. There is no doubt that host immunological responses play a pivotal role in the pathogenesis of the disease and diversity of the clinical forms of tegumentary leishmaniasis. The finding that the Th1 type of immune response, which is characterized by the production of high levels of IFN-γ (the main cytokine involved in microphage activation), is associated with pathology rather than protection has led to the understanding of the pathogenesis of L. braziliensis infection 3, 4 . These studies have not only increased our knowledge of how the infection progresses toward disease, but also have implications in therapy for leishmaniasis and vaccine development. However, it is clear that host immune response alone is unlikely to help elucidate how a single genus is able to cause such a heterogeneous group of diseases.
Recent epidemiologic, biochemical, and molecular biology studies indicate that L.(V.) braziliensis is polymorphic 5, 6 . Moreover, there is an association between intra-species differences in L. (V.) braziliensis and clinical forms of tegumentary leishmaniasis 7 . Isolates of the same species of leishmania play a role in the therapeutic response to antimony. Drug-resistant strains among different Leishmania species have been reported, suggesting that the parasites are capable of adapting to drug pressure. Susceptibility to antimony varies among species and even between geographically distant strains of L. (V.) braziliensis. There is also evidence that L. (V.) braziliensis isolates may have susceptibility or resistance to nitric oxide; isolates resistant to nitric oxide in vitro have been derived from human cases in which antimony therapy failed 8 . Reports also indicate that parasite resistance to hydrogen peroxide may play a role in more severe forms of leishmaniasis. Leishmania guyanensis isolates capable of metastasizing in hamsters possess cytoplasmic peroxiredoxin and peroxidase activities different from those of non-metastatic parasites 9 . Moreover, L. guyanensis with a metastatic phenotype has isoforms of tryparedoxin peroxidase and elongation factor 1 beta different from those of non-metastatic strains. These studies show that intra-species differences of leishmania are associated with clinical forms of the disease as well as response to therapy. Knowledge about genotypic differences may also affect the diagnosis of leishmaniasis. For instance, the initial form of tegumentary leishmaniasis caused by L. (V.) braziliensis is cutaneous leishmaniasis. Patients with cutaneous lesions will develop mucosal or disseminated leishmaniasis only after days or weeks. Mucosal leishmaniasis requires higher doses of antimony to cure it. Meanwhile, disseminated leishmaniasis responds poorly to antimony therapy; in such cases, amphotericin B is the drug of choice. Advances in molecular biology are expected to make it possible to determine whether a strain is associated with a risk for the development of mucosal or disseminated leishmaniasis on the basis of the genotypic characteristics of the isolate.
The number of studies showing a role of the vector in the epidemiology and pathogenesis of leishmania infections has grown exponentially in the last 10 years. A great variety of phlebotomine sandfly vectors have been documented in Brazil, and a large proportion of them are exposed to Leishmania spp. infection. Lutzomyia whitmany and Lutzomyia intermedia are the most important vectors of L.(V.) braziliensis in Brazil. The salivary glands of phlebotomines have biochemical and immunological properties. Initial studies showing that administering the salivary glands of L. longipalps with Leishmania major increased parasite growth and pathology and prompted many subsequent studies; these studies indicate that not only do the salivary glands of sandflies play a role in the pathogenesis of leishmaniasis, but also that these salivary gland proteins are targets for vaccines against leishmaniasis. It is important to note that the ability of salivary gland proteins to modulate immunological responses varies by Lutzomyia species. For instance, while immunological responses against salivary gland proteins of L. longipalps and Phlebotomus papatasi are associated with protection against leishmaniasis, evidence of an immune response against the L. intermedia salivary gland proteins is associated with the development of cutaneous leishmaniasis 10 .
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